Can-Fite Advances Two Drug Candidates Through Phase III Trials with FDA and EMA Backing — Can-Fite BioPharma Ltd.

Event summary

Namodenoson, an A3AR agonist for advanced liver cancer, is in a pivotal Phase III study under FDA and EMA guidance.
Piclidenoson, another A3AR agonist, is advancing through Phase III trials for moderate-to-severe plaque psoriasis.
Namodenoson has received FDA Fast Track and Orphan Drug designations from both the FDA and EMA.
Can-Fite aims to leverage these regulatory pathways toward potential marketing approvals in the U.S. and Europe.

The big picture

Can-Fite's progress with Namodenoson and Piclidenoson underscores the strategic importance of securing regulatory backing early in Phase III trials. This approach not only streamlines the path to market but also enhances the company's valuation as it moves closer to potential approvals for high-unmet medical needs in oncology and inflammatory diseases.

What we're watching

Regulatory Pathways: How the FDA Fast Track and Orphan Drug designations will accelerate Namodenoson's approval process for hepatocellular carcinoma.
Clinical Trial Outcomes: Whether Piclidenoson can successfully navigate its Phase III trials to become a viable treatment for plaque psoriasis.
Commercialization Timing: The pace at which Can-Fite can transition from late-stage clinical development to commercialization of its drug candidates.